At the time of writing, Amicus Therapeutics Inc [FOLD] stock is trading at $11.97, up 14.00%. An important factor to consider is whether the stock is rising or falling in short-term value. The FOLD shares have gain 19.10% over the last week, with a monthly amount glided 9.72%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on September 06, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $18. Previously, Wells Fargo started tracking the stock with Overweight rating on May 30, 2024, and set its price target to $18. On May 14, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $13 on the stock. Morgan Stanley upgraded its rating to a Overweight and increased its price target to $20 on December 19, 2023. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $14 as its price target on September 09, 2022. In a note dated January 14, 2022, SVB Leerink upgraded an Outperform rating on this stock and boosted its target price from $12 to $16.
For the past year, the stock price of Amicus Therapeutics Inc fluctuated between $9.02 and $14.57. Currently, Wall Street analysts expect the stock to reach $15.25 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $11.97 at the most recent close of the market. An investor can expect a potential return of 27.4% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
According to Amicus Therapeutics Inc [NASDAQ:FOLD], the company’s sales were 455.65M for trailing twelve months, which represents an 34.04% jump. Gross Profit Margin for this corporation currently stands at 0.88% with Operating Profit Margin at -0.06%, Pretax Profit Margin comes in at -0.22%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.86 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.05 points at the first support level, and at 10.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.63, and for the 2nd resistance point, it is at 13.30.
Ratios To Look Out For
It is important to note that Amicus Therapeutics Inc [NASDAQ:FOLD] has a current ratio of 2.75. On the other hand, the Quick Ratio is 2.26, and the Cash Ratio is 1.25. Considering the valuation of this stock, the price to sales ratio is 7.79, the price to book ratio is 26.77.
Transactions by insiders
Recent insider trading involved Campbell Bradley L, President and CEO, that happened on Oct 01 ’24 when 7500.0 shares were sold. Director, BRADLEY CAMPBELL completed a deal on Oct 01 ’24 to buy 7500.0 shares. Meanwhile, President and CEO Campbell Bradley L sold 7500.0 shares on Sep 03 ’24.
